Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04548219 · ClinicalTrials.gov registry record · Phase 1
A Study to Compare Two Different Formulations of Mirikizumab in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT04548219 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 60 participants.
The verdict
NCT04548219, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to compare two different formulations of mirikizumab in healthy participants. This study will compare how much of each formulation gets into the blood stream and how long it takes the body to remove it. Information about any side effects that may occur will also be collected. Participants will remain in the study for about 12 weeks, after receiving study drug.
Interventions
- DRUG Mirikizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2020-09-11 |
| Est. Completion | 2021-01-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04548219
The ClinicalTrials.gov registry entry for NCT04548219 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Mirikizumab is the first listed.
NCT04548219 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04548219 about?
NCT04548219 is a clinical study titled "A Study to Compare Two Different Formulations of Mirikizumab in Healthy Participants". The purpose of this study is to compare two different formulations of mirikizumab in healthy participants. This study will compare how much of each formulation gets into the blood stream and how long it takes the body to remove it. Information about any side effects that may occur will also be colle...
What is the current status of trial NCT04548219?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2020-09-11. Estimated completion is 2021-01-11.
What interventions are being tested in trial NCT04548219?
The interventions under investigation include: Mirikizumab (DRUG).
Who is sponsoring clinical trial NCT04548219?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.